Regarding Pfizer's new crown "special effect medicine", the results of this research are surprising

On August 25, local time, the Associated Press published an article entitled "Study: PFIZER COVID PILL Showed No Benefit in Younger Adults) Essence

In the first paragraph of this article, the Associated Press stated that a large -scale study released on Wednesday found that Pfizer's new crown special medicine Paxlovid can "reduce the risk of hospitalization and death of high -risk elderly people, but for younger adults The effect is "hard or no" ("Little or No Benefit".

According to the Associated Press, the research published in the International Magazine of the New England Medical Journal of Internationally renowned is Israel's result of the investigation of 109,000 new crown cases. Specifically, the study found that if PAXLOVID is used in the short term after the new crown is infected, 75%of the elderly who are 65 and over the age of 65 and above can be hospitalized. However PaxLovid cannot bring these people to measure the benefits.

However, the Associated Press pointed out that this study itself also has some limitations. For example, its data is directly integrated from Israel's huge medical system, rather than adopting the standard practices of clinical detection of drugs, such as random and double -blindness. Essence The Associated Press also said that the cause of this result may be that most of the younger adults have been infected or vaccinated, because this itself can greatly reduce their risk of hospitalization and death.

However, the Associated Press believes that the results of this Israeli study may still bring some new questions to the US government, which pushed Paxlovid. Earlier, the United States Biden administration has invested more than $ 10 billion to buy this drug and supplies pharmacies from all over the United States.

U.S. experts who have not participated in this study also told the Associated Press that although Paxlovid has no effect on the younger adults, this drug is still important for people with severe high -risk people.

In the end, the Associated Press said that Pfizer refused to comment on the matter.

- END -